Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SANTA CLARA, Calif., Oct. 10, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO™ model in a European based laboratory. The establishment of this improved translational model provides the European scientific community with unfettered access to an advanced research tool for use in preclinical studies of obesity, dysmetabolism and type 2 diabetes.
The FATZO™ is a next generation preclinical research model for obesity, metabolic disorders, diabetes and related complications. The unique feature of an intact leptin system enables the FATZO model to provide novel scientific insights into the physiological and cellular mechanisms that lead from obesity / metabolic disorders to diabetes. It examines polygenic causes of obesity and mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia and hyperinsulinemia.
“Obesity and diabetes have a significant global impact, affecting more than 422 million people worldwide. We expanded our FATZO™ model to ensure European researchers have ready access to the best translational tools available to advance the drug development programs aimed at curing these diseases,” said Jim Wang, M.D., Crown Bioscience’s Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research.
“The establishment of our FATZO™ model in Europe is pivotal to Crown Bioscience’s commitment to providing translational models that are representative of human conditions of obesity, type 2 diabetes and related comorbidities,” said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. “We look forward to working with European scientists to help answer their most challenging questions about these diseases and enable more effective drug discovery for their treatment.”
For more information on CrownBio’s commitment to advance the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
